Thomas W Storer1, Shalender Bhasin1, Thomas G Travison1, Karol Pencina1, Renee Miciek1, Jennifer McKinnon1, Shehzad Basaria1. 1. Research Program in Men's Health: Aging and Metabolism (T.W.S., S.Bh., T.G.T., K.P., J.M., S.Ba.), Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, and Harvard T.H. Chan School of Public Health (R.M.), Boston, Massachusetts 02115; and Hebrew SeniorLife Institute for Aging Research (T.G.T.), Roslindale, Massachusetts 02131.
Abstract
CONTEXT: Testosterone increases skeletal muscle mass and strength, but the effects of testosterone on aerobic performance in mobility-limited older men have not been evaluated. OBJECTIVE: To determine the effects of testosterone supplementation on aerobic performance, assessed as peak oxygen uptake (V̇O2peak) and gas exchange lactate threshold (V̇O2θ), during symptom-limited incremental cycle ergometer exercise. DESIGN: Subgroup analysis of the Testosterone in Older Men with Mobility Limitations Trial. SETTING: Exercise physiology laboratory in an academic medical center. PARTICIPANTS: Sixty-four mobility-limited men 65 years or older with low total (100-350 ng/dL) or free (<50 pg/dL) testosterone. INTERVENTIONS: Participants were randomized to receive 100-mg testosterone gel or placebo gel daily for 6 months. MAIN OUTCOME MEASURES: V̇O2peak and V̇O2θ from a symptom-limited cycle exercise test. RESULTS:Mean (SD) baseline V̇O2peak was 20.5 (4.3) and 19.9 (4.7) mL/kg/min for testosterone and placebo, respectively. V̇O2peak increased by 0.83 (2.4) mL/kg/min in testosterone but decreased by -0.89 (2.5) mL/kg/min in placebo (P = .035); between group difference in change in V̇O2peak was significant (P = .006). This 6-month reduction in placebo was greater than the expected -0.4-mL/kg/min/y rate of decline in the general population. V̇O2θ did not change significantly in testosterone but decreased by 1.1 (1.8) mL/kg/min in placebo, P = .011 for between-group comparisons. Hemoglobin increased by 1.0 ± 3.5 and 0.1 ± 0.8 g/dL in testosterone and placebo groups, respectively. CONCLUSION:Testosterone supplementation in mobility-limited older men increased hemoglobin and attenuated the age-related declines in V̇O2peak and V̇O2θ. Long-term intervention studies are needed to determine the durability of this effect.
RCT Entities:
CONTEXT: Testosterone increases skeletal muscle mass and strength, but the effects of testosterone on aerobic performance in mobility-limited older men have not been evaluated. OBJECTIVE: To determine the effects of testosterone supplementation on aerobic performance, assessed as peak oxygen uptake (V̇O2peak) and gas exchange lactate threshold (V̇O2θ), during symptom-limited incremental cycle ergometer exercise. DESIGN: Subgroup analysis of the Testosterone in Older Men with Mobility Limitations Trial. SETTING: Exercise physiology laboratory in an academic medical center. PARTICIPANTS: Sixty-four mobility-limited men 65 years or older with low total (100-350 ng/dL) or free (<50 pg/dL) testosterone. INTERVENTIONS:Participants were randomized to receive 100-mg testosterone gel or placebo gel daily for 6 months. MAIN OUTCOME MEASURES: V̇O2peak and V̇O2θ from a symptom-limited cycle exercise test. RESULTS: Mean (SD) baseline V̇O2peak was 20.5 (4.3) and 19.9 (4.7) mL/kg/min for testosterone and placebo, respectively. V̇O2peak increased by 0.83 (2.4) mL/kg/min in testosterone but decreased by -0.89 (2.5) mL/kg/min in placebo (P = .035); between group difference in change in V̇O2peak was significant (P = .006). This 6-month reduction in placebo was greater than the expected -0.4-mL/kg/min/y rate of decline in the general population. V̇O2θ did not change significantly in testosterone but decreased by 1.1 (1.8) mL/kg/min in placebo, P = .011 for between-group comparisons. Hemoglobin increased by 1.0 ± 3.5 and 0.1 ± 0.8 g/dL in testosterone and placebo groups, respectively. CONCLUSION:Testosterone supplementation in mobility-limited older men increased hemoglobin and attenuated the age-related declines in V̇O2peak and V̇O2θ. Long-term intervention studies are needed to determine the durability of this effect.
Authors: K Sreekumaran Nair; Robert A Rizza; Peter O'Brien; Ketan Dhatariya; Kevin R Short; Ajay Nehra; Janet L Vittone; George G Klee; Ananda Basu; Rita Basu; Claudio Cobelli; Gianna Toffolo; Chiara Dalla Man; Donald J Tindall; L Joseph Melton; Glenn E Smith; Sundeep Khosla; Michael D Jensen Journal: N Engl J Med Date: 2006-10-19 Impact factor: 91.245
Authors: Thomas G Travison; Shehzad Basaria; Thomas W Storer; Alan M Jette; Renee Miciek; Wildon R Farwell; Karen Choong; Kishore Lakshman; Norman A Mazer; Andrea D Coviello; Philip E Knapp; Jagadish Ulloor; Anqi Zhang; Brad Brooks; Ahn-Hoa Nguyen; Richard Eder; Nathan LeBrasseur; Ayan Elmi; Erica Appleman; Leife Hede-Brierley; Geeta Bhasin; Ashmeet Bhatia; Antonio Lazzari; Samuel Davis; Pengsheng Ni; Lauren Collins; Shalender Bhasin Journal: J Gerontol A Biol Sci Med Sci Date: 2011-06-22 Impact factor: 6.053
Authors: Shalender Bhasin; Linda Woodhouse; Richard Casaburi; Atam B Singh; Ricky Phong Mac; Martin Lee; Kevin E Yarasheski; Indrani Sinha-Hikim; Connie Dzekov; Jeanne Dzekov; Lynne Magliano; Thomas W Storer Journal: J Clin Endocrinol Metab Date: 2004-11-23 Impact factor: 5.958
Authors: Martin Stout; Garry A Tew; Helen Doll; Irena Zwierska; Nicola Woodroofe; Kevin S Channer; John M Saxton Journal: Am Heart J Date: 2012-10-30 Impact factor: 4.749
Authors: K F Reid; T W Storer; K M Pencina; R Valderrabano; N K Latham; L Wilson; C Ghattas; R Dixon; A Nunes; N Bajdek; G Huang; S E Skeels; A P Lin; S M Merugumala; H J Liao; M L Bouxsein; R D Zafonte; S Bhasin Journal: BMC Musculoskelet Disord Date: 2022-05-25 Impact factor: 2.562